COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)
NCT04380896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3502
Last updated 2022-09-27
Summary
This study will perform prospective repeated serological antibody testing on a cohort of at least 1000 healthcare workers at Great Ormond Street Hospital. Within this cohort, a subset of 150-250 staff members with confirmed (PCR positive) SARS-CoV-2 disease will be followed with intensive monthly testing for 6 months to determine whether antibody levels in the blood are maintained or decrease during this time. All 1000 recruited healthcare workers will be followed 6-monthly
Conditions
Interventions
- OTHER
-
Blood test
Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
- OTHER
-
Standardised questionnaires
It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
Sponsors & Collaborators
-
Great Ormond Street Hospital for Children NHS Foundation Trust
lead OTHER
Principal Investigators
-
Louis Grandjean, Dr · Great Ormond Street Hospital NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-04-27
- Primary Completion
- 2022-07-30
- Completion
- 2022-07-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines
NCT00121823 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global)
NCT04626076 ·Status: COMPLETED
-
Clinical Investigation of Infections Due to Leishmanial Parasites
NCT00001169 ·Status: COMPLETED
-
Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia
NCT00537953 ·Status: UNKNOWN ·Phase: PHASE2
-
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
NCT00600548 ·Status: COMPLETED ·Phase: PHASE2
-
Break-through Infection Following Mpox vaccinatIon
NCT05522296 ·Status: COMPLETED
-
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
NCT05621928 ·Status: ACTIVE_NOT_RECRUITING
-
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
NCT00469495 ·Status: COMPLETED ·Phase: NA
-
Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
NCT01218893 ·Status: COMPLETED ·Phase: NA
-
Low Antimonial Dosage in American Mucosal Leishmaniasis
NCT01301937 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
NCT05433285 ·Status: COMPLETED ·Phase: PHASE3
-
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
NCT01422954 ·Status: COMPLETED ·Phase: NA
-
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
NCT04805216 ·Status: COMPLETED
-
Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)
NCT06293339 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers
NCT05532293 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia
NCT00487253 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)
NCT04211649 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).
NCT06997159 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
NCT05409261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
NCT03929016 ·Status: COMPLETED ·Phase: PHASE1
-
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
NCT01082341 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
NCT05426577 ·Status: UNKNOWN
-
Diagnosis and Treatment of Leishmania Infections
NCT00344188 ·Status: RECRUITING
-
Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
NCT00317980 ·Status: COMPLETED ·Phase: PHASE4
-
101-PGC-005 for the Treatment of COVID-19
NCT05656521 ·Status: UNKNOWN ·Phase: PHASE2